373110
Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. Xcell Therapeutics Inc. was incorporated in 2015 and is based in Seoul, South Korea.
373110 (373110) - Total Liabilities
Latest total liabilities as of September 2024: ₩7.93 Billion KRW
Based on the latest financial reports, 373110 (373110) has total liabilities worth ₩7.93 Billion KRW as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
373110 - Total Liabilities Trend (2022–2024)
This chart illustrates how 373110's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
373110 Competitors by Total Liabilities
The table below lists competitors of 373110 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
RLF Agtech Ltd
AU:RLF
|
Australia | AU$18.82 Million |
|
Mangalam Global Enterprise Limited
NSE:MGEL
|
India | ₹5.10 Billion |
|
Danel (Adir Yeoshua) Ltd
TA:DANE
|
Israel | ILA838.21 Million |
|
Noram Lithium Corp
OTCQB:NRVTF
|
USA | $1.19 Million |
|
Mudajaya Group Bhd
KLSE:5085
|
Malaysia | RM1.14 Billion |
|
Leishen Energy Holding Co., Ltd. Ordinary Shares
NASDAQ:LSE
|
USA | $23.88 Million |
|
Biofrontera Inc
NASDAQ:BFRI
|
USA | $18.00 Million |
|
The Good Flour Corp
PINK:GFCOF
|
USA | $4.04 Million |
Liability Composition Analysis (2022–2024)
This chart breaks down 373110's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.38 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 373110's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 373110 (2022–2024)
The table below shows the annual total liabilities of 373110 from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩7.77 Billion | -3.91% |
| 2023-12-31 | ₩8.08 Billion | +15.08% |
| 2022-12-31 | ₩7.03 Billion | -- |